{
    "data": [
        {
            "id": "69a09e5c24c37e0001bb990d",
            "title": "Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Bristol Myers Squibb Co. </strong><a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"BMY\" href=\"https://www.benzinga.com/quote/BMY\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/BMY\" target=\"_blank\">BMY</a>)<!-- --> shares are down on Thursday as the company releases <a href=\"https://www.benzinga.com/pressreleases/26/02/b50881681/systimmune-and-bristol-myers-squibb-highlight-positive-phase-iii-interim-topline-results-for-izalo\" rel=\"noreferrer noopener\" target=\"_blank\">positive interim results</a> from a Phase 3 trial of izalontamab brengitecan (Iza-bren), in collaboration with <strong>SystImmune Inc.</strong></p><!--/$--><!--$--><p class=\"block core-block\">This news comes as the broader market experienced mixed performance, with the Nasdaq slightly down while other indices showed modest gains.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Breast Cancer Trial Data</h2><!--/$--><!--$--><p class=\"block core-block\">SystImmune’s parent company, <strong>Sichuan Biokin Pharmaceutical Co., Ltd., </strong>reported that Iza-bren met its dual primary endpoints of progression-free survival and overall survival in the interim analysis of the trial.</p><!--/$--><!--$--><p class=\"block core-block\">The trial patients with unresectable locally advanced or metastatic triple-<a href=\"https://www.benzinga.com/general/health-care\" rel=\"noreferrer noopener\" target=\"_blank\">negative breast cancer</a> (TNBC) whose disease progressed following prior taxane therapy.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">The update marks the third Phase 3 study where Iza-bren has achieved its primary endpoints, underscoring its potential in treating advanced triple-negative breast cancer.</p><!--/$--><!--$--><p class=\"block core-block\">The trial results indicate a statistically significant improvement in patient outcomes compared to chemotherapy options, which could lead to new treatment avenues for patients facing limited options. </p><!--/$--><!--$--><p class=\"block core-block\">Additionally, the drug has received Breakthrough Therapy Designation from both the U.S. FDA and China’s National Medical Products Administration for multiple indications.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The broader market experienced gains on the previous trading day, with the S&amp;P 500 closing up 0.06% and the Dow Jones rising 0.13%. </p><!--/$--><!--$--><p class=\"block core-block\">Bristol Myers Squibb’s rise aligns with the overall positive sentiment, although the Technology sector saw a slight decline of 0.02%, indicating mixed conditions across different sectors.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">Currently, the stock is trading 4.1% below its 20-day simple moving average (SMA) and 9.8% below its 100-day SMA, indicating some short-term weakness.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Over the past 12 months, shares have increased, and they are currently positioned closer to their 52-week highs than lows, suggesting a strong performance relative to its historical range.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 44.45, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum for the stock.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $63.00</li>\n<li><strong>Key Support</strong>: $60.00</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/NYSE:BMY/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $60.09. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>RBC Capital</strong>: Initiated with Sector Perform (Target $60.00) (Feb. 25)</li>\n<li><strong>Piper Sandler</strong>: Overweight (Raises Target to $75.00) (Feb. 23)</li>\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $75.00) (Feb. 20)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>BMY Price Action:</strong> Bristol-Myers Squibb shares were down 0.56% at $60.95 at the time of publication on Thursday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904840\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Breast-cancer.jpeg",
            "link": "https://www.benzinga.com/markets/large-cap/26/02/50904840/bristol-myers-says-new-breast-cancer-drug-shows-survival-benefit-in-pretreated-patients",
            "pub_date": "2026-02-27 03:26:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a09cc524c37e0001bb97ed",
            "title": "COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Novavax Inc.</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"NVAX\" href=\"https://www.benzinga.com/quote/NVAX\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVAX\" target=\"_blank\">NVAX</a>)<!-- --> shares are up on Thursday following the company’s announcement of its fourth-quarter and <a href=\"https://www.benzinga.com/pressreleases/26/02/n50884747/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights\" rel=\"noreferrer noopener\" target=\"_blank\">full-year 2025 financial</a> results.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Earnings</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Novavax reported <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">fourth-quarter earnings</a> of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase.</p><!--/$--><!--$--><p class=\"block core-block\">Novavax on Thursday said it beat its 2025 cost-cutting targets across both GAAP and Non-GAAP R&amp;D and SG&amp;A spending and is tightening future expense goals.</p><!--/$--><!--$--><p class=\"block core-block\">The company now expects Non-GAAP R&amp;D and SG&amp;A expenses (net of R&amp;D reimbursements) of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 (newly introduced target).</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Management Commentary</h2><!--/$--><!--$--><p class=\"block core-block\">“In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts,” said <strong>John Jacobs</strong>, President and CEO, Novavax.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">Novavax highlighted a revenue forecast for 2026, projecting adjusted total revenue between $230 million and $270 million compared to the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $381.22 million</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects to achieve $35 million to $45 million in Nuvaxovid product sales and $40 million to $50 million in adjusted supply sales, reflecting ongoing collaborations with partners like the Serum Institute.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">Currently, the stock is trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength. Over the past 12 months, shares have increased significantly and are currently positioned closer to their 52-week highs than lows, reflecting a strong upward trend.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is not available, but the absence of significant crossovers indicates a stable trend without immediate bullish or bearish pressure.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and the absence of a MACD signal suggests mixed momentum, indicating that traders should watch for potential breakout or reversal signals in the near term.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $12.00</li>\n<li><strong>Key Support</strong>: $10.50</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Hold Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:NVAX/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $32.23. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>BTIG</strong>: Buy (Maintains Target to $19.00) (Jan. 20)</li>\n<li><strong>JP Morgan</strong>: Underweight (Lowers Target to $6.00) (Nov. 18, 2025)</li>\n<li><strong>B. Riley Securities</strong>: Buy (Lowers Target to $16.00) (Nov. 10, 2025)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>NVAX Price Action:</strong> Novavax shares were up 21.15% at $11.55 at the time of publication on Thursday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904546\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Novavax-Vaccine.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50904546/covid-19-vaccine-maker-novavax-swings-to-profit-as-sales-climb",
            "pub_date": "2026-02-27 03:19:37",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a09d3024c37e0001bb9837",
            "title": "Stock Of The Day: False Breakout In Nvidia?",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">It may be staging a classic false breakout.  This would suggest a continued move lower. It's why Nvidia is the <strong>Stock of the Day.</strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>     •  What’s weighing on<a href=\"https://www.benzinga.com/quote/NVDA\" rel=\"noreferrer noopener\" target=\"_blank\"> NVDA shares?</a></strong></p><!--/$--><!--$--><p class=\"block core-block\">It is unfortunate that technical analysis has a dubious reputation on Wall Street. But it isn't surprising.</p><!--/$--><!--$--><p class=\"block core-block\">Most technical analysts don't understand market dynamics and price action. They look for patterns on charts without understanding why these patterns form and what they mean. </p><!--/$--><!--$--><p class=\"block core-block\">This is why so many technical analysts are unsuccessful.</p><!--/$--><!--$--><p class=\"block core-block\">Chart patterns are graphical illustrations of the supply and demand dynamics playing out in a market. A classic ascending triangle pattern formed on the chart of Nvidia. These are considered bullish patterns.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">As you can see on the chart, there was resistance around the $193.40 level going back to December. The line is horizontal because the sellers were patient. They were okay with staying at their prices and waiting for the buyers to come to them.</p><!--/$--><!--$--><p class=\"block core-block\">But over the same time period, traders and investors who wanted to buy became anxious and impatient. They were willing to pay successively higher prices. This is why the support line of the pattern is ascending.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">The ascending triangle is bullish because it is a graphical illustration of a market with patient and complacent sellers, and aggressive and impatient buyers. Regardless of the market, these dynamics can set the stage for a move higher.</p><!--/$--><!--$--><p class=\"block core-block\">But successful traders know that popular stocks such as Nvidia can act very differently than analysts and pundits anticipate. Just because a stock gets above resistance, it doesn't mean it will stay there.</p><!--/$--><!--$--><p class=\"block core-block\">It could end up being a false breakout. It looks like there is going to be a breakout, but then the stock reverses quickly and heads lower. As you can see on the chart, that may be the case today with Nvidia.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Successful traders understand the dynamics that form patterns on charts. But they also understand that there are no rules in markets, only guidelines. The ability to remain flexible is one of the main reasons for their success.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Michael Vi  via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50904633\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Nvidia-Corporation.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/technicals/26/02/50904633/stock-of-the-day-false-breakout-in-nvidia",
            "pub_date": "2026-02-27 03:21:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a098fa24c37e0001bb9579",
            "title": "Beast Industries CEO: BitMine Is &#39;Leader In Ethereum Staking Market&#39;",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Beast Industries</strong> CEO <strong>Jeff Housenbold </strong>on Thursdaycalled <strong>BitMine</strong> <a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"BMNR\" href=\"https://www.benzinga.com/quote/BMNR\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/BMNR\" target=\"_blank\">BMNR</a>)<!-- --> “a leader in the <strong>Ethereum</strong> <a class=\"ticker-link\" data-exchange=\"CRYPTO\" data-ticker=\"ETH\" href=\"https://www.benzinga.com/quote/ETH-USD\" rel=\"noopener\" target=\"_blank\">(CRYPTO: </a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/eth/usd\" target=\"_blank\">ETH</a>)<!-- --> staking market” critical to stablecoin infrastructure, explaining the company’s $200 million investment.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">The Beast Industries Connection</h3><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Beast Industries, backed by <strong>MrBeast’s</strong> media empire with 1.45 billion users, <a href=\"https://www.benzinga.com/crypto/cryptocurrency/26/01/49934861/mr-beast-receives-200-million-investment-by-tom-lees-bitmine\" target=\"_blank\">invested</a> $200 million in BitMine earlier this year.  </p><!--/$--><!--$--><p class=\"block core-block\">Housenbold <a href=\"https://x.com/TomLeeUpdates/status/2027045447815078039\" target=\"_blank\">pointed</a> out the strategic rationale on CNBC’s Squawk Box on Thursday, saying, “Ethereum is the backbone of stablecoin and the blockchain,” he added.</p><!--/$--><!--$--><p class=\"block core-block\">He emphasized the importance of the DeFi movement for consumers, highlighting greater access, democratization, lower cost of capital, and the ability to move capital globally in a safe and secure way.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">Beast Industries is rapidly expanding beyond media into consumer products including Feastables chocolate, toy lines, protein snacks with Jack Link’s, and the Lunchly business.</p><!--/$--><!--$--><p class=\"block core-block\">The company recently acquired Step, a six-year-old fintech focused on financial education for young people.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">The Ethereum Thesis</h3><!--/$--><!--$--><p class=\"block core-block\">The investment rationale centers on Ethereum’s role as stablecoin infrastructure. </p><!--/$--><!--$--><p class=\"block core-block\">BitMine owns 4,422,659 ETH valued at approximately $8.7 billion, making it the world’s largest corporate Ethereum holder.</p><!--/$--><!--$--><p class=\"block core-block\">BitMine has 3,040,483 staked ETH generating $249 million in annual staking rewards at current rates. </p><!--/$--><!--$--><p class=\"block core-block\">This staking dominance positions BitMine as critical infrastructure for the Ethereum network’s security and operation.</p><!--/$--><!--$--><p class=\"block core-block\">The connection to Beast Industries centers on stablecoin-powered financial services. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">As Beast expands into fintech with the Step acquisition, Ethereum-based stablecoins provide the rails for low-cost global payments and financial services targeting Gen Z and Gen Alpha audiences.</p><!--/$--><!--$--><h3 class=\"wp-block-heading\">The Technical Breakdown</h3><!--/$--><!--$--><p class=\"block core-block\">BMNR is accelerating through critical support levels. All EMAs sit overhead: 20 EMA at $20.42, 50 EMA at $22.56, 100 EMA at $26.28, and 200 EMA at $30.69.</p><!--/$--><!--$--><p class=\"block core-block\">The Supertrend at $18.84 flipped green below price, but today’s violent decline threatens this support. </p><!--/$--><!--$--><p class=\"block core-block\">The stock broke below the recent consolidation zone around $21-$22, confirming sellers are in full control.</p><!--/$--><!--$--><p class=\"block core-block\">Critical support at $18.84 is under immediate threat. </p><!--/$--><!--$--><p class=\"block core-block\">Breaking below $18 likely cascades toward the ultimate support zone at $12-$15. </p><!--/$--><!--$--><p class=\"block core-block\">Today’s 6.5% collapse represents capitulation selling with minimal support visible until that lower zone.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50903983\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Los-Angeles--Ca---Mar-4--2023-Mrbeast--J.jpeg",
            "link": "https://www.benzinga.com/crypto/cryptocurrency/26/02/50903983/beast-industries-ceo-bitmine-is-leader-in-ethereum-staking-market",
            "pub_date": "2026-02-27 03:03:26",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0993d24c37e0001bb95cf",
            "title": "Zoom Boasts Strong Q4, Scores Big &#39;Displacement Wins&#39;: Analyst",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Zoom Communications Inc <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"ZM\" href=\"https://www.benzinga.com/quote/ZM\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/ZM\" target=\"_blank\">ZM</a>)<!-- --> </strong>reported strong fourth-quarter and full-year results, supported by enterprise resilience and displacement wins, according to Rosenblatt Securities.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>The Zoom Communications </strong><strong>Analyst: </strong><a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst/585aa876b5a482000151d0ed/catharine-trebnick\" target=\"_blank\">Analyst Catharine Trebnick</a> maintained a Buy rating and price target of $115.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>The Zoom Communications </strong><strong>Thesis:</strong> The company's results reflected modest revenue growth, resilient enterprise trends and best-in-class profitability, Trebnick said in the note.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Check out <a href=\"https://www.benzinga.com/analyst-stock-ratings\" target=\"_blank\">other analyst stock ratings</a></strong>.</p><!--/$--><!--$--><p class=\"block core-block\">Zoom's total revenues grew 5.3% year-on-year in the fourth quarter to $1,247 billion, exceeding Street estimates by approximately $12 million, she added.</p><!--/$--><!--$--><p class=\"block core-block\">\"Zoom Phone ARR continued to grow in the mid teens, supported by several landmark enterprise displacement wins, including a Fortune 10 customer for 140,000 seats,\" the analyst wrote. ZCX (Zoom Customer Experience) ARR grew in high double digits, she further stated.</p><!--/$--><!--$--><p class=\"block core-block\">All the top 10 CX deals included paid AI, with seven involved \"competitive displacements of leading CCaaS incumbents,\" Trebnick mentioned.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>ZOOM Price Action:</strong> Shares of Zoom had declined by 13.38% to $74.00 at the time of publication on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-middle-50904063\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Zoom.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50904063/zoom-communications-displacement-wins-says-bullish-analyst",
            "pub_date": "2026-02-27 03:04:33",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}